论文部分内容阅读
晚期卵巢癌行彻底减瘤术后通常选用卡铂/顺铂加紫杉醇方案化疗。经此一线方案化疗后仍有20％～30％病例有小的残留灶需要进一步处理。Ⅱ和Ⅲ期临床研究显示:拓普特肯(topotecan)对包括使用铂类治疗失败的卵巢癌病例有效。将其用于经卡铂加紫杉醇治疗后仍有残留灶的晚期卵巢癌患者。 为探讨拓普特肯疗效及毒性。将其选择使用一线化疗药物(标准的卡铂加紫杉醇方案)治疗后经剖腹术或腹腔镜证实有小的残留灶(直经<2cm),组织学证实为上皮性卵巢癌
Advanced ovarian cancer after complete tumor reduction surgery is usually selected carboplatin / cisplatin plus paclitaxel chemotherapy. After this first-line chemotherapy after chemotherapy is still 20% to 30% of cases have small residual lesions need further treatment. Phase II and III clinical studies have shown that topotecan is effective in patients with ovarian cancers that have failed treatment with platinum. It will be used in patients with advanced ovarian cancer who have residual disease after carboplatin plus paclitaxel treatment. To explore Topotecan efficacy and toxicity. They were selected to use first-line chemotherapy drugs (standard carboplatin plus paclitaxel regimen) after treatment by laparotomy or laparoscopy confirmed a small residual lesions (straight <2cm), histologically confirmed as epithelial ovarian cancer